No Data
No Data
Betta Pharmaceuticals (300558): 1Q24 performance improvement focuses on marginal positive performance trends
The 2023 and 1Q24 results are in line with our and market expectations. The company announced 2023 and 1Q24 results: revenue of 2,456 billion yuan, YoY +3.3%; net profit to mother of 348 million yuan, right
Betta Pharmaceutical (300558.SZ): Thebesilil tartrate capsules completed phase III clinical trials and obtained a summary report
Zhitong Finance App News, Betta Pharmaceutical (300558.SZ) issued an announcement. After completing the phase III clinical trial of the company's self-developed project BPI-16350 (tebesilil tartrate capsules), a clinical trial summary report has been obtained through a series of statistical data analysis work. This drug, in combination with fluvirizin, is suitable for patients with locally advanced or advanced recurrent metastatic breast cancer with positive hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2), which progresses after previous endocrine treatment. The study results showed that, based on the researcher's evaluation, the BPI-16350+ fluvir group was previously accepted
Express News | Betta Pharmaceuticals: BPI-16350 obtained phase III clinical trial summary report
Betta Pharmaceuticals revealed behind the layoffs: last year's profit did not increase revenue, R&D personnel fell 13%
The 2023 financial report shows that there is a phenomenon where profit increases do not increase revenue, and management expenses have dropped sharply. Some industry insiders questioned that layoffs and lower management expenses increased their current profits, but the sustainability of this method needs to be considered.
Donghai Securities released a research report on April 23 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is in line with expectations, and overall cost control is good;
Donghai Securities released a research report on April 23 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is in line with expectations, and overall cost control is good; 2) ensartinib is growing rapidly, and the volume of new drugs is expected to be marketed in 24 years; 3) the R&D pipeline continues to advance, and endogenous development and external cooperation go hand in hand. (Mainichi Keizai Shimbun)
Great Wall Guorui Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side returned to growth, and management and financial expe
Great Wall Guorui Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side returned to growth, and management and financial expenses fell sharply; 2) the rapid release of ensatinib and a solid step in internationalization; 3) the two newly launched products provided increased performance and continued progress in the research pipeline; 4) maintained the growth trend in the first quarter of this year, and EYP-1901 phase II clinical data showed treatment potential. (Mainichi Keizai Shimbun)
No Data